Connect with us

Business

Pfizer Advances Once-Daily Weight Loss Pill After Early Study Success

Published

on

Pfizer Advances Once-Daily Weight Loss Pill After Early Study Success

Pfizer is advancing a once-daily version of its weight loss medication, danuglipron, following encouraging findings from an ongoing early-stage study. The pharmaceutical company announced on Thursday that it has identified a formulation that shows a favorable safety profile and effective bodily response.

The company plans to carry out more early-stage trials in the latter half of this year to determine the optimal dosage, with results expected by the first quarter of next year. These results will be pivotal for the registration enabling studies required for regulatory approval.

Dr. Mikael Dolsten, Pfizer’s outgoing Chief Scientific Officer, expressed optimism about the drug’s potential, stating, “Danuglipron has demonstrated good efficacy in a twice-daily formulation, and we believe a once-daily formulation has the potential to have a competitive profile in the oral GLP-1 space.” Notably, the study found no liver safety issues with the once-daily formulations.

Advertisement

Pfizer is among several pharmaceutical companies racing to capture a share of the market for GLP-1 agonists, a class of drugs highly sought after for weight loss and diabetes management. Analysts predict this market could be worth approximately $100 billion by the end of the decade.

Despite this potential, Pfizer has faced challenges breaking into the GLP-1 space. In December, the company discontinued a twice-daily version of danuglipron due to patient tolerance issues in a mid-stage study. Investor confidence was further dampened when Pfizer scrapped another once-daily pill in June 2023 after patients showed elevated liver enzymes. These setbacks, alongside the decline of its Covid business, have impacted Pfizer’s stock performance.

Nonetheless, Pfizer continues to develop other experimental obesity drugs and maintains a robust pipeline of three clinical and several pre-clinical candidates. “Obesity is a key therapeutic area for Pfizer,” Dolsten emphasized.

Advertisement

Competitors Novo Nordisk and Eli Lilly have seen rising demand for their injectable GLP-1 drugs, despite high costs and limited insurance coverage. These companies, along with Pfizer, are striving to develop oral versions that are more convenient for patients and easier to produce, which could help alleviate supply shortages in the U.S.

Pfizer has also indicated it may pursue acquisitions or partnerships with smaller obesity drugmakers. CEO Albert Bourla mentioned in January that while acquiring a late-stage obesity treatment is unlikely, the company is exploring potential licensing deals or earlier-stage weight loss drugs as part of its strategic focus on cost management.

Advertisement
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

IMF Warns Prolonged Iran Conflict Could Push Global Economy Toward Recession

Published

on

IMF Warns Prolonged Iran Conflict Could Push Global Economy Toward Recession

The International Monetary Fund has warned that the global economy faces a serious risk of slipping into recession if the ongoing conflict involving Iran, the United States, and Israel continues and keeps energy prices elevated.

In its latest World Economic Outlook report, the IMF outlined a worst-case scenario in which oil, gas, and food prices surge and remain high through 2026. Under such conditions, global economic growth could fall below 2% next year — a level historically associated with near-recession conditions worldwide.

“This would mean a close call for a global recession, which has happened only four times since 1980,” the IMF noted, pointing to the most recent downturn during the COVID-19 pandemic.

Advertisement

Energy markets have been under intense pressure since the conflict escalated more than six weeks ago, particularly after disruptions to the Strait of Hormuz, a vital shipping corridor for global oil and gas supplies. The collapse of peace talks between Washington and Tehran has further heightened uncertainty.

The IMF cautioned that the most severe economic impact would occur if oil prices average $110 per barrel this year and rise to $125 by 2027. In that scenario, global inflation could climb as high as 6% next year, potentially forcing central banks to raise interest rates to contain price pressures.

IMF Chief Economist Pierre-Olivier Gourinchas said that while defining a global recession can be complex, growth around 2% would feel like one for many people worldwide, with rising unemployment and increased food insecurity in several regions.

Advertisement

Although oil prices briefly approached $120 per barrel during the conflict, they have since eased, trading at around $98.85 as of Tuesday. However, the IMF stressed that the risk of recession would increase significantly if current disruptions persist over an extended period.

A quicker resolution to the conflict could help stabilise the outlook. The IMF said that if fighting subsides in the coming weeks and energy production normalises by mid-year, global growth in 2026 could reach 3.1%, slightly below its earlier forecast of 3.3%.

Among advanced economies, the United Kingdom is expected to be the hardest hit by the energy shock, with growth forecast downgraded to 0.8% this year before a modest recovery to 1.3%.

Advertisement

Oil-exporting nations in the Gulf are also projected to face significant economic strain. Iran’s economy is expected to contract by 6.1% this year, though it could rebound by 3.2% in 2027 if the conflict ends soon.

Elsewhere in the region, Qatar — a major supplier of liquefied natural gas — has seen key infrastructure targeted, including the Ras Laffan industrial complex. Its economy is forecast to shrink by 8.6% in 2026 before rebounding strongly the following year.

Neighbouring Iraq is also expected to suffer a 6.8% slowdown this year, followed by a projected recovery to 11.3% growth in 2027. Meanwhile, Saudi Arabia is forecast to maintain positive growth of 3.1% in 2026, accelerating to 4.5% the year after.

Advertisement
Continue Reading

Business

Dolce & Gabbana co-founder steps down as chair

Published

on

Dolce & Gabbana co-founder steps down as chair

Stefano Gabbana, co-founder of Dolce & Gabbana, has stepped down as chair of the company he established in 1985 alongside Domenico Dolce.

The move comes as the luxury fashion house navigates mounting financial challenges, including a debt burden of approximately €450m (£391m/$528m), alongside a broader slowdown in the global luxury retail market. Reduced consumer spending—particularly in China—has added pressure on high-end brands.

Despite stepping down from the chairmanship, Gabbana will remain deeply involved in the creative direction of the brand, continuing his longstanding collaboration with Dolce in designing collections and maintaining the identity that has defined the label for decades.

Advertisement

Leadership responsibilities have transitioned to Alfonso Dolce, brother of Domenico Dolce and the company’s chief executive, who officially assumed the role of chair on 1 January. Corporate filings indicate that Gabbana communicated his decision internally in December.

In response to shifting market dynamics, Dolce & Gabbana has been expanding into new sectors, including hospitality and home furnishings. Its recent offerings feature high-end lifestyle pieces such as a leopard-print porcelain vase priced at £1,084, reflecting an effort to diversify revenue streams.

Industry observers highlight the scale of the company’s financial obligations. Fashion expert Priya Raj noted that the brand remains privately owned, with both Gabbana and Domenico Dolce each holding significant 40% stakes—leaving open questions about future ownership structures.

Advertisement

Reports in March indicated that the company had engaged financial advisers and entered discussions with creditors as it seeks to manage its debt. In a statement on Friday, the firm confirmed that negotiations with banks are ongoing, declining further comment at this stage.

Despite financial headwinds and past controversies—including criticism earlier this year during Milan Fashion Week over a predominantly white model cast, which drew backlash from figures like Bella Hadid—the brand has demonstrated resilience. Analysts note that its distinctive aesthetic continues to attract a loyal global following, even as industry trends evolve.

Advertisement
Continue Reading

Business

Universal Music Receives $64bn Takeover Bid From Pershing Square

Published

on

Universal Music Receives $64bn Takeover Bid From Pershing Square

Universal Music Group has received a takeover offer valued at approximately $64.3bn (£48bn), in a potential deal that could reshape the global music industry.

The bid has been made by Pershing Square Capital Management, whose billionaire chief executive Bill Ackman said the proposal would involve a merger and lead to the combined company being listed in the United States. Pershing Square already holds a stake in Universal.

Universal Music, the world’s largest music company, represents a wide roster of global stars including Taylor Swift, Sabrina Carpenter and Kendrick Lamar. It also owns iconic assets such as Abbey Road Studios and major record labels including EMI and Island Records.

Advertisement

The company has yet to respond publicly to the offer.

Ackman praised Universal’s leadership, saying it had built a “world-class artist roster” and delivered strong business performance. He added that the company had successfully adapted to industry changes, particularly by embracing opportunities presented by artificial intelligence while safeguarding intellectual property.

However, he argued that Universal’s stock had underperformed due to factors unrelated to its core business, suggesting these issues could be resolved through the proposed transaction.

Advertisement

Pershing Square’s broader investment portfolio includes stakes in major technology firms such as Google, Meta Platforms and Amazon, as well as Restaurant Brands International, the parent company of Burger King.

Market analysts note that while Universal dominates the global music industry—home to nine of the top 10 recording artists of 2025—its revenue growth is closely tied to streaming platforms like Spotify and Apple Music, where slower-than-expected growth has raised concerns.

Although global music revenues have rebounded in recent years thanks to streaming subscriptions, debates continue over royalty payments to artists. At the same time, the rise of AI-generated deepfake music—where fraudsters imitate established artists—has emerged as a growing challenge for the industry.

Advertisement

In a letter to Universal’s board, Ackman said the company had “dramatically underperformed” key stock indexes, citing uncertainty around a significant stake held by Bolloré Group, controlled by billionaire Vincent Bolloré, as well as delays to a planned New York listing.

Continue Reading

Trending